TIRmed Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.68M
- Investors
-
8
TIRmed Pharma General Information
Description
Developer of a non-steroid treatment of eczema designed to dampen inflammation and relieve itching caused due to innate immune responses. The company offers chemically stabilized single-stranded oligonucleotide formulated in a cream form, enabling atopic dermatitis patients with self-applied and easy-to-use at-home anti-itch treatment.
Contact Information
Website
www.pharmability.comCorporate Office
- Alviksvägen 1
- 167 53 Stockholm
- Sweden
Corporate Office
- Alviksvägen 1
- 167 53 Stockholm
- Sweden
TIRmed Pharma Timeline
TIRmed Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 09-Apr-2025 | $4.68M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 01-Jan-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 20-Nov-2020 | Completed | Generating Revenue | |||
| 2. Grant | 01-Dec-2019 | $55.3K | $170K | Completed | Startup | |
| 1. Early Stage VC | $170K | $170K | Completed | Startup |
TIRmed Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TIRmed Pharma Patents
TIRmed Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022229350-A2 | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections | Inactive | 30-Apr-2021 | ||
| WO-2022229350-A3 | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections | Inactive | 30-Apr-2021 | ||
| EP-3679136-A1 | Single stranded oligonucleotides inhibiting endocytosis | Pending | 06-Sep-2017 | ||
| ES-2834906-T3 | Single chain oligonucleotides for use in the medical treatment of skin disorders | Active | 15-Jun-2015 | ||
| CA-2989371-A1 | Single-stranded oligonucleotides for use in the medical treatment of skin disorders | Active | 15-Jun-2015 | C12N15/117 |
TIRmed Pharma Signals
TIRmed Pharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sciety | Venture Capital | Minority | ||
| Nolsterby Invest | Family Office | Minority | ||
| Almi Invest | Venture Capital | Minority | ||
| STOAF (Stockholms Affärsänglar) | Venture Capital | Minority | ||
| European Union | Government |
TIRmed Pharma FAQs
-
When was TIRmed Pharma founded?
TIRmed Pharma was founded in 2018.
-
Where is TIRmed Pharma headquartered?
TIRmed Pharma is headquartered in Stockholm, Sweden.
-
What is the size of TIRmed Pharma?
TIRmed Pharma has 6 total employees.
-
What industry is TIRmed Pharma in?
TIRmed Pharma’s primary industry is Drug Discovery.
-
Is TIRmed Pharma a private or public company?
TIRmed Pharma is a Private company.
-
What is TIRmed Pharma’s current revenue?
The current revenue for TIRmed Pharma is .
-
How much funding has TIRmed Pharma raised over time?
TIRmed Pharma has raised $6.69M.
-
Who are TIRmed Pharma’s investors?
Sciety, Nolsterby Invest, Almi Invest, STOAF (Stockholms Affärsänglar), and European Union are 5 of 8 investors who have invested in TIRmed Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process